Thiết kế dựa trên cấu trúc của một số dẫn xuất quinazoline như là các chất ức chế thụ thể yếu tố tăng trưởng biểu bì

Song J, Jang S, Lee JW, Jung D, Lee S, Min KH (2019) Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors. Bioorg Med Chem Lett 29(3):477–480

Hanan EJ, Baumgardner M, Bryan MC, Chen Y, Eigenbrot C, Fan P et al (2016) 4-Aminoindazolyl-dihydrofuro [3, 4-d] pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase. Bioorg Med Chem Lett 26(2):534–539

Kong L-L, Ma R, Yao M-Y, Yan X-E, Zhu S-J, Zhao P et al (2017) Structural pharmacological studies on EGFR T790M/C797S. Biochem Biophys Res Commun 488(2):266–272

Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF et al (2006) Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor–mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12(21):6494–6501

Dungo RT, Keating GM (2013) Afatinib: first global approval. Drugs. 73(13):1503–1515

Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C et al (2012) Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 343(2):342–350

Tsao M-S, Sakurada A, Cutz J-C, Zhu C-Q, Kamel-Reid S, Squire J et al (2005) Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med 353(2):133–144

Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ et al (2014) AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 4(9):1046–1061

Walter AO, Sjin RTT, Haringsma HJ, Ohashi K, Sun J, Lee K et al (2013) Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov 3(12):1404–1415

Park K, Lee J-S, Lee KH, Kim J-H, Cho BC, Min YJ et al (2016) Olmutinib (BI 1482694; HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: efficacy and safety at the RP2D. J Clin Oncol 34(suppl):abstr 9055

Paz-Ares L, Tan E-H, O’byrne K, Zhang L, Hirsh V, Boyer M et al (2017) Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol 28(2):270–277

Song Z, Ge Y, Wang C, Huang S, Shu X, Liu K et al (2016) Challenges and perspectives on the development of small-molecule EGFR inhibitors against T790M-mediated resistance in non-small-cell lung cancer: miniperspective. J Med Chem 59(14):6580–6594

Beheshti A, Pourbasheer E, Nekoei M, Vahdani S (2016) QSAR modeling of antimalarial activity of urea derivatives using genetic algorithm–multiple linear regressions. J Saudi Chem Soc 20(3):282–290

Khan MF, Verma G, Akhtar W, Shaquiquzzaman M, Akhter M, Rizvi MA et al (2019) Pharmacophore modeling, 3D-QSAR, docking study and ADME prediction of acyl 1, 3, 4-thiadiazole amides and sulfonamides as antitubulin agents. Arab J Chem. 12:5000-18.

Zhang L, Yang Y, Zhou H, Zheng Q, Li Y, Zheng S et al (2015) Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors. Eur J Med Chem 102:445–463

Ibrahim MT, Uzairu A, Shallangwa GA, Ibrahim A (2018) Computational studies of some biscoumarin and biscoumarin thiourea derivatives as⍺-glucosidase inhibitors. J Eng Exact Sci 4(2):0276–0285

Mills N. ChemDraw Ultra 10.0 CambridgeSoft, 100 CambridgePark Drive, Cambridge, MA 02140. www. cambridgesoft. com. Commercial Price: 1910fordownload, 2150 for CD-ROM; Academic Price: 710fordownload, 800 for CD-ROM. ACS Publications; 2006.

Kohn W, Becke AD, Parr RG (1996) Density functional theory of electronic structure. J Phys Chem 100(31):12974–12980

Ibrahim MT, Uzairu A, Shallangwa GA, Ibrahim A (2020) In-silico studies of some oxadiazoles derivatives as anti-diabetic compounds. J King Saud Univ Sci. 32:423-432.

Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7:42717

Ismail SY, UZAIR A, Sagagi B (2019) Insilico studies of sulfur-containing shikonin oxime derivatives as inhibitors of mgc 803 gastric cancer cell line. J Eng Exact Sci 5(1):0079–0089

Ibrahim MT, Uzairu A, Uba S, Shallangwa GA (2020) Computational modeling of novel quinazoline derivatives as potent epidermal growth factor receptor inhibitors. Heliyon. 6(2):e03289

Batool M, Ahmad B, Choi S (2019) A structure-based drug discovery paradigm. Int J Mol Sci 20(11):2783

Khan I, Garikapati KR, Setti A, Shaik AB, Makani VKK, Shareef MA et al (2019) Design, synthesis, in silico pharmacokinetics prediction and biological evaluation of 1, 4-dihydroindeno [1, 2-c] pyrazole chalcone as EGFR/Akt pathway inhibitors. Eur J Med Chem 163:636–648

Hosen S, Dash R, Khatun M, Akter R, Bhuiyan MHR, Rezaul M et al (2017) In silico ADME/T and 3D QSAR analysis of KDR inhibitors. J Appl Pharm Sci 7(01):120–128

Ibrahim MT, Uzairu A, Shallangwa GA, Uba S (2020) Computer-aided molecular modeling studies of some 2, 3-dihydro-[1, 4] dioxino [2, 3-f] quinazoline derivatives as EGFR WT inhibitors. Beni-Suef Univ J Basic Appl Sci 9:1–10

Ibrahim MT, Uzairu A, Shallangwa GA, Uba S (2020) In-silico activity prediction and docking studies of some 2, 9-disubstituted 8-phenylthio/phenylsulfinyl-9 h-purine derivatives as anti-proliferative agents. Heliyon. 6(1):e03158